Kornimate/medical-research-clean huggingface dataset:
local anesthetic infusion and sternotomy

Conditions: Hyperalgesia; Pain

Summary: cardiac surgery often induces acute postoperative pain and moreover chronic dysesthesia frequently occur long-term after sternotomy. the high doses of intraoperative opioïds are well known to enhance postoperative hyperalgesia (ha) and a perioperative local anesthetic agent infusion is one of the therapeutic strategies used to limit this phenomena. the aim of this study was to evaluate the effectiveness of a continuous ropivacaïne sternal infusion compared with a saline serum infusion to limit postoperative ha, pain and morphine consumption (m) after sternotomy in cardiac surgery. this strategy could lead to lower postoperative morphine consumption and opioïd induced hyperalgesia.

* principal objective: comparison of peri-incisionnal dynamic hyperalgesia extend evaluated by von frey filament during the first postoperative week between the two groups. * secondary objective: comparison of peri-incisionnal static hyperalgesia (pain threshold) extend evaluated by von frey filament, postoperative pain scores, morphine consumption, hemodynamic and respiratory parameters during the first postoperative week and incidence of chronic pain and dysesthesia at six month between the two groups. ropivacaïne plasmatic concentration will be monitored, during infusion. * study design : monocentric, double blind randomized clinical trial comparing two groups of patients with a same intraoperative anesthetic management : * group 1: ropivacaïne infiltration before skin incision followed by a 48 hours ropivacaïne continuous infusion after surgery through a sternal fenestrated catheter * group 2: same protocol with pre and postoperative saline infusion postoperative pain management is identical in the two groups based upon a morphine sulfate pca pump for the first 48 hours. • number of subjects : 40 patients, 20 in each group

Eligibility criteria:
inclusion criteria: * patients aged from 50 to 75 years old * asa score : 1-3 * cardiac surgery with median sternotomy for: * single valve replacement, bentall, bahnson, tyrone david procedure * single or multiple cardiac artery bypass grafting (cabg) * combined surgery (valve replacement + cabg) * without predicted risk of postoperative complication * informed consent obtained from the patient * patient beneficiating of social insurance exclusion criteria: * patient refusal to participate in the study * drug or alcohol abuse history * analgesic or opioid consumption within the 12 hours preceding the surgery * chronic use of analgesic drugs or history of chronic pain * disability to understand morphine pca use * allergy to ropivacaine or other local anaesthesia * patient treated by fluvoxamine or enoxamine * patient suffering for liver insufficiency (child score \>a) * patient with major preoperative hypovolemia

Keywords: sternotomy postoperative hyperalgesia intralesional anesthetic infusion ropivacaïne chronic postoperative pain cardiac surgery sternum cardiac surgical procedures
cpap vs autocpap for treatment of obstructive sleep apnea (osa) in the postoperative setting

Conditions: Obstructive Sleep Apnea

Summary: the purpose of this study is to determine if an autoadjusting cpap machine is better than the regular cpap machine in treatment of obstructive sleep apnea in the postoperative setting.

the purpose of this study is to determine if an autoadjusting cpap machine is better than the regular cpap machine in treatment of obstructive sleep apnea in the postoperative setting. patients with known obstructive sleep apnea who are on cpap therapy at home and undergo an elective surgery (meeting specified inclusion and exclusion criteria) will be randomized to either using autoadjusting cpap vs their usual cpap at their prescribed settings the night after surgery. during that night, they will be monitored with full polysomnography in their hospital bed.

Eligibility criteria:
inclusion criteria: 1. known osa patients well-controlled by cpap (not hypoxemic i.e. oxygen saturation (sao2) ≥ 89% and post-treatment apnea hypopnea (ahi) \ 3 hours per night) presenting for elective inpatient surgery to metrohealth medical center 2. elective extremity or lower abdominal surgery 3. age \>18 years exclusion criteria: 1. surgery that may cause hypoxemia from causes other than the effect on upper airway patency e.g. any thoracic surgery, upper abdominal surgery, head and neck surgery. 2. surgery on the upper-airway. 3. any condition that may interfere with application of cpap mask e.g. trauma, surgery on the face, vomiting, naso-gastric intubation etc. 4. osa treated with a device other than cpap e.g. bilevel positive pressure or v-positive airway pressure 5. osa needing very high levels of cpap i.e. \> 16 cms to achieve adequate control 6. osa or other underlying cardiopulmonary conditions that require supplemental oxygen 7. patients with decompensated congestive heart failure or advanced chronic obstructive pulmonary disease (copd) (fev1\<35% of predicted) 8. patients with neuromuscular impairment 9. patients with central sleep apnea 10. pregnant patients 11. decisional impaired subjects who are not able to consent

Keywords: obstructive sleep apnea hypopnea syndrome osa postoperative cpap
an investigational drug study in obese (considerably overweight) patients (0364-006)

Conditions: Obesity

Summary: the purpose of this study is to determine the safety and effectiveness of an investigational drug in patients with obesity (considerably overweight).


Eligibility criteria:
inclusion criteria: * patients who are obese (considerably overweight) based on body mass index. exclusion criteria: * patients with serious or unstable current or past medical conditions

Keywords: obesity and obesity-related medical conditions
the effectiveness of intravitreal avastin injection for crvo

Conditions: Central Retinal Vein Occlusion

Summary: to determine the effectivness of intravitreal avastin injection on visual acuity on people that suffer from central retinal vein occlusion


Eligibility criteria:
inclusion criteria: * patients above 18 years old * suffer from crvo * maximal visual acuity 6/15 exclusion criteria: * va of lp * retinal disease other than crvo * incomplete medical record * follow up less than 6 months
cd19-targeting car t cells for b cell lymphoma

Conditions: B Cell Lymphoma

Summary: the purpose of this study is to evaluate the safety and efficacy of cd19-targeting car t cells infusion for b cell lymphoma.

chimeric antigen receptor (car) t cells targeting cd19 will be evaluated for safety and efficacy in patients with b cell lymphoma or leukemia. the car consists of a cd19 targeting antibody scfv with two intracellular signaling domains derived from cd3 zeta and cd28. autologous t cells will be gene-engineered with the car gene using a retrovirus vector. prior to t cell infusion, the patients will be subjected to preconditioning treatment. after t cell infusion, the patients will be evaluated for 24 months for adverse reactions, persistence of car t cells and efficacy.

Eligibility criteria:
inclusion criteria: 1. relapsed or refractory cd19+ b-cell lymphoma. 2. measurable disease. 3. performance status ecog 0-2. 4. age:18-80. 5. fertile females/males must consent to use contraceptives during participation of the trial. 6. signed informed consent exclusion criteria: 1. any significant medical or psychiatric illness that would prevent the patient from giving informed consent or from following the study procedures. 2. patients with primary cns lymphoma. 3. known human immunodeficiency virus (hiv) infection. 4. active and/or severe infection (e.g. tuberculosis, sepsis and opportunistic infections, active hepatitis b virus (hbv) or active hepatitis c virus (hcv) infection). 5. other serious underlying medical conditions, which, in the investigator's judgment, could impair the ability of the patient. 6. treatment with an investigational product within 30 days prior to enrollment, or at least 5 half lives of that drug, which is longest. 7. patients that do not consent to that tissue and blood samples are stored in a biobank. 8. pregnancy.

Keywords: cd19 car t cells lymphoma
effect of stress and exercize on the outcome after chemo-radiation

Conditions: Glioblastoma (GBM)

Summary: glioblastoma (gbm) is a highly malignant, incurable primary brain tumor. due to the nature of this disease and the extent of the treatment (surgery followed by chemoradiation according to the stupp trial) patients undergo considerable psychological distress. it is known that stress hormones are involved in a wide range of processes involved in cell survival, cell cycle and immune function, and can cause therapy resistance. in this study the effect of stress on outcome after chemoradiation in patients with gbm will be investigated.

psychological stress will be measured using multiple approaches; physiological measures, stress biomarker and questionnaires. using this approach, a broad insight in the relationship between stress and outcome after chemoradiation will be obtained and the potential influence of physical activity and sleep evaluated. in addition, the results of this study will help to identify patients which experience high stress levels during chemoradiation to pilot (in the future) interventions to reduce stress before and during treatment.

Eligibility criteria:
inclusion criteria: * patients treated with stupp or elderly protocol: gbm who iv, astrocytoma who iv idhmt, astrocytoma who ii idhwt (gbm-like). * willing to wear the smart watch during the treatment protocol exclusion criteria: * younger than 18 years * not in possession of a smart phone

Keywords: stress glioblastoma survival quality of life
incidence and outcome of paracentesis induced circulatory dysfunction in acute-on-chronic liver failure.

Conditions: Acute on Chronic Liver Failure

Summary: all consecutive patients admitted in ilbs from may 2015 to december 2016.aclf (acute on chronic liver failure). aclf will be randomize into group 1: mvp (modest volume paracentesis) of less than 5 liters with iv albumin at a dose 8 gms/l of ascitic fluid group 2: mvp (modest volume paracentesis) of less than 5 liters without albumin


Eligibility criteria:
inclusion criteria: 1. all patients with acute hepatic insult manifesting as jaundice (sr. bil. ≥ 5 mg/dl) and coagulopathy (inr≥1.5), complicated within 4 weeks by ascites and/or encephalopathy in a patient with previously diagnosed or undiagnosed chronic liver disease (aclf) admitted in the hospital. 2. all cirrhotics decompensated with ascites admitted in the hospital. 3. grade ii/iii ascites 4. need for paracentesis. exclusion criteria: 1. age \ 75 years 2. hepatocellular carcinoma 3. non cirrhotic ascites such as malignancy or tubercular peritonitis 4. serum cr \>1.5mg% 5. refractory septic shock 6. grade iii/iv hepatic encephalopathy 7. abdominal wall cellulitis 8. active variceal bleed 9. respiratory, cardiac and renal failure 10. refusal to participate in the study
evaluation of recombinant factor xiii for prevention of bleeding in patients with fxiii inherited deficiency

Conditions: Congenital Bleeding Disorder; Congenital FXIII Deficiency

Summary: the trial is conducted in europe, north america and asia. the aim of this trial is to evaluate catridecacog (recombinant factor xiii (rfxiii)) treatment in patients with inherited fxiii deficiency. it is expected that recombinant fxiii can be used for the prevention of bleeding episodes.


Eligibility criteria:
inclusion criteria: * diagnosis of congenital fxiii a-subunit deficiency (confirmed by genotyping at screening visit) * treatment with regular fxiii replacement therapy initiated at least 6 months prior to screening and one of the following : a documented history of at least one 1 treatment-requiring bleeding episode prior to initiation of regular replacement therapy or a documented family history of fxiii congenital deficiency (only for subjects on regular replacement therapy prior to screening) * documented history of at least two 2 bleeding episodes requiring treatment with fxiii containing blood products within the last 12 months prior to screening (only for subjects receiving on-demand treatment prior to screening) exclusion criteria: * known neutralizing antibodies (inhibitors) towards fxiii * any known congenital or acquired coagulation disorder other than congenital fxiii deficiency * documented history of at least 2 treatment-requiring bleeding episodes per year during previous regular replacement therapy with fxiii containing blood products (fresh frozen plasma (ffp), plasma-derived fxiii (pd fxiii) and cryoprecipitate) * known or suspected allergy to trial product(s) or related products * planned major surgery during the trial period. catheter, ports and dental extractions do not count as surgeries and will not exclude the subject * renal insufficiency defined as current dialysis therapy * any history of confirmed venous or arterial thrombo-embolic events
effect of manual diaphragmatic activation on diaphragm function in patients with gastroesophageal reflux disease

Conditions: Diaphragm Dysfunction

Summary: this study was conducted to investigate effect of manual diaphragmatic activation on diaphragm function in patients with gastroesophageal reflux disease

thirty both gender patients with gastroesophageal reflux disease enrolled in this study , study group and control group. to investigate effect of manual diaphragmatic activation on diaphragm function in patients with gastroesophageal reflux disease

Eligibility criteria:
inclusion criteria: * patients with gastroesophageal reflux disease. * the age will be ranged from 20 to 50 . * body mass index from 20 to 34,9 kg/m2 . * low level of physical therapy exclusion criteria: * pregnancy * open wound * abdominal or spinal surgery * congenital or acquired disorder
hook plate vs tightrope in fixation of fracture distal third clavicle

Conditions: Fracture Clavicle

Summary: to compare the clinical \& radiological outcomes of hook plate \& tightrope fixation in fracture of lateral third clavicle.

adult clavicle fractures account for 4% to 10% of fractures. distal clavicle fractures occurs in 25% to 30% of all clavicle fracture.the management of fractures of the distal clavicle has been a matter of debate in literature. neer in 1968 suggested a new classification and proposed general treatment guidelines . type i and type iii fractures are generally treated non-operatively. for type ii fractures, surgical management is the treatment of choice .there are numerous operative techniques reported in the past. the methods of surgical treatment could be summarised as follows: 1. fixation in terms of k-wires and different pins such as the steinmann pin, and knowles pin. this fixation could also be augmented with concomitant tension band wires 2. coracoclavicular indirect fixation with the use of screws, suture anchors, dacron graft or mersilene tape 3. open reduction and clavicular plate fixation with the use of different plate systems such as the balser plate,locked plate,hook plate, etc. different surgical techniques have their own advantages and disadvantages with more than 20 techniques described so far, no single fixation is ideal and perfect. there is still no consensus regarding the best surgical method to fix these fracture ,the investigators choose two of the most common of these methods and evaluate \& compare best radiological \& clinical outcomes of both.

Eligibility criteria:
inclusion criteria: * adults (over 16 years old) including both sexes. * acute fractures within 3 weeks of injury. * isolated \& closed fractures. exclusion criteria: * pathological fracture of distal clavicle. * deteriorated general health. * previous history of dysfunction with the affected shoulder. * incomplete medical records or lost to follow up.
ankle kinesio taping on balance and functional performance in obese females.

Conditions: Obesity

Summary: obesity is one of the most dangerous factors affecting the joints, which must be prevented due to arthritis and the long-lasting, tiring effects that affect a person's life \[1\], the most important of these are foot problems due to weight and excess pressure, it is also one of the factors that greatly affects walking movement because it increases the load on joint movement, this increases the risk of musculoskeletal diseases.

it had been reported that obese subjects have a higher prevalence of falls and ambulatory stumbling or a loss of balance than their non-obese counterparts. excess weight increases the stress within the bones, joints, and soft tissues, resulting in impaired musculoskeletal function. such as abnormal mechanics of the body. these impairments, such as impaired balance, gait, strength, sensory function, and neuromuscular function have been identified as strong risk factors for falls. participants that are eligible to participate to the study will be distributed into two groups: group a will receive ankle kinesiotaping on the dominant leg. while, group b will receive placebo kinesiotaping on the dominant leg. the treatment duration will be 6 weeks for both groups.

Eligibility criteria:
inclusion criteria: * female students between 18 and 25 years old * bmi of 30 kg/ m2 or more exclusion criteria: * orthopedic or neurosurgery injury past 6 months * ankle edema * skin allergy to the tape * abnormalities of the nervous system * any previous history of injury * use of medication in the past 3 months * regular physical activity at least three times a week
jmt101 in combination with osimertinib, versus cisplatin-pemetrexed in participants with locally advanced or metastatic non-small cell lung cancer (nsclc) characterized by epithermal growth factor receptor (egfr) exon 20ins mutations

Conditions: Local Advanced or Metastatic NSCLC

Summary: this is a multicenter, randomized, open-label, parallel-controlled phase 3 study. this study aims to evaluate the efficacy and safety of jmt101 combined with osimertinib compared with cisplatin combined with pemetrexed in participants with local advanced or metastatic non-small-cell lung cancer harboured egfr 20ins mutation without prior systemic therapy. primary objective of this study is to assess the efficacy of jmt101 combined with osimertinib versus cisplatin combined with pemetrexed using by （independent review center）irc-assessed progression free survival (pfs) per recist 1.1 as primary endpoint. approximately 398 participants are estimated to be randomized into the study. participants enrolled will be randomized to jmt101 or cisplatin chemotherapy in a 1:1 manner, stratified by baseline brain metastasis (with/without) and eastern cooperative oncology group (ecog) performance status (ps) (0 versus 1).


Eligibility criteria:
inclusion criteria: 1. age between 18-75 years old. 2. histologically or cytologically confirmed diagnosis of nsclc, locally advanced (stage iiib and iiic according to the 8th edition of the iaslc tnm staging criteria) or metastatic (stage iv), not suitable for curative therapy. for central laboratory confirmation of egfr exon 20 insertion mutation with tumour tissue/blood sample. 3. at least 1 measurable lesion per recist version 1.1 4. life expectancy ≥ 12 weeks 5. eastern cooperative oncology group (ecog) performance status of 0 to 1 6. adequate organ and hematologic function exclusion criteria: 1. prior treatment with any systemic anti-cancer therapy for locally advanced or metastatic nsclc. 2. central nervous system metastasis with associated symptom and signs. 3. concurrent egfr mutations: exon 19 deletion, l858r, t790m, g719x, s768i, or l861q. 4. history of interstitial lung disease, or infectious pneumonitis need heavy antibiotics therapy 5. as judged by the investigator, unsuitable for attending the study.

Keywords: harboring egfr 20ins mutation without prior systemic therapy
perioperative outcome of infraumbilical versus a modified intraumbilical direct trocar insertion

Conditions: Gynecologic Disease

Summary: laparoscopic surgery is now a well-established alternative to open surgery for many gynecological disorders owing to its faster wound healing, shorter hospital stay, less postoperative pain, and better cosmetic results. postoperative scar cosmoses is a critical issue for women, especially for young women. these scars may have negative impacts, such as psychological consequences. the symptoms associated with the wound, such as pain, tenderness, and itching, can be induced by the scars


Eligibility criteria:
inclusion criteria: * all women subjected to direct trocar application as a part of any gynecologic procedure performed exclusion criteria: * verres needle insertion. * patients with previous abdominal surgery and scar, * umbilical hernia, * previous laparoscopy or previous umbilical surgery, * burns in the umbilical region; * who have hyperpigmented skins.
influence of osteopathic intervention on cervical muscles in tension headaches in women

Conditions: Tension Headaches

Summary: this study aims to understand whether there is any relationship between the intervention on the trapezius, sternocleidomastoid and suboccipital muscles in patients with chronic tension headaches.

it is expected to find an improvement in the symptoms and frequency of tension headaches. in this study, the investigators intend to see the effects of trapezius and sternocleidomastoid "stretching techniques", and "suboccipital inhibition" on tension headaches. to collect data, volunteers were asked to fill out the headache impact test (hit-6).

Eligibility criteria:
inclusion criteria: * tension headaches; * being over eighteen years of age; exclusion criteria: * loss of mobility of cervical; * cervical and shoulder pain during episodes; * other headaches (migraine, cervicogenic headache...) * other interventions and/or pharmacological treatment a few days before the intervention; * epilepsy; * trauma.

Keywords: tension headaches trapezius stretching sternocleidomastoid stretching suboccipital inhibition manual therapy osteopathy hit-6